Autres langues MediPharm Labs Corp.

Actions

LABS

CA58504D1006

Marché Fermé - Toronto S.E. Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,075 ^CAD	0,00%		-6,25%	+15,38%

26/06	Transcript : MediPharm Labs Corp. - Shareholder/Analyst Call
20/06	MediPharm Labs acquiert les droits pour les produits avancés à base de cannabis médical de Remidose Aerosols	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

MediPharm Labs Announces Voting Results From the 2024 Annual Meeting of Shareholders	26/06
MediPharm Labs Announces Voting Results From the 2024 Annual Meeting of Shareholders	26/06
MediPharm Labs Acquires Rights for Advanced Medical Cannabis Products From Remidose Aerosols	20/06
MediPharm Labs to Acquire Rights for Advanced Medical Cannabis Products From Remidose Aerosols	20/06
MediPharm Labs Corp. Brief: Acquiring Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols	20/06
MediPharm Labs Acquires Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols	20/06
MediPharm Labs Q1 Gross Profit, Rise	15/05
MediPharm Labs Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
MediPharm Labs Corp. Brief: Anticipates further improvement on profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1-$2 Million	15/05
MediPharm Labs Corp. Brief: Revenue increased 67% to $9.8 Million during the three months ended March 31, 2024, versus revenue for the same quarter in 2023 of $5.8 Million	15/05
MediPharm Labs Reports First Quarter Results	15/05
MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results	08/05
MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5%	27/03
MediPharm Labs Provides Conference Call Recording Details	27/03
MediPharm Labs Narrows Q4 Loss, Revenue Grows	27/03
MediPharm Labs Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
MediPharm Labs Corp. Brief: Q4 Revenue $9.131 Million; Says Annual Revenue and Adjusted EBITDA Improve by 50%	27/03
MediPharm Labs Reports Fourth Quarter and Full Year Results	27/03
MediPharm Labs Offers Update on German Cannabis Legalization; Up Nearly 6%	25/03
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023	25/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MediPharm Labs Corp.

Actions

LABS

CA58504D1006

Autres langues

Filtres